Weight-loss medications such as Ozempic and Wegovy are now available to non-insured customers at several major grocery chains, including Costco, Sam’s Club, and Hy-Vee. These retailers have begun offering the medications at a significantly reduced price of $499 per month, making them more accessible to those without insurance.
On October 3, 2023, Costco announced its partnership with Novo Nordisk, the manufacturer of these weight-loss drugs. Members of the Costco Member Prescription Program can purchase a month’s supply of either medication, provided they have a valid prescription. This initiative comes as a response to the skyrocketing costs of these treatments, which can reach up to $1,350 without insurance or discounts, according to GoodRx.
Major Retailers Expand Access to Weight-Loss Drugs
Both Ozempic and Wegovy contain the same active ingredient, semaglutide, but serve different purposes. Wegovy is specifically designed for chronic weight management, while Ozempic is intended for the treatment of type 2 diabetes. Ozempic’s official website notes its effectiveness in improving blood sugar levels in adults with type 2 diabetes and reducing the risk of serious cardiovascular events, such as heart attacks and strokes.
Sam’s Club has also joined the effort to provide affordable access to these medications. Members can buy a month’s supply for $499 without needing insurance. Additionally, Sam’s Club offers same-day pharmacy delivery for various medications, including those that require refrigeration, catering to members who may need immediate access to treatments.
On the same day, Hy-Vee, a grocery chain based in Iowa with locations across eight Midwestern states, announced it would partner with GoodRx to offer both medications at the same price of $499. Customers can obtain their prescriptions at Hy-Vee pharmacy counters, and those who have a GoodRx coupon can unlock further savings by presenting it at the pharmacy.
Addressing Medication Shortages and Affordability
The U.S. Food and Drug Administration (FDA) reported that the years-long shortage of these popular medications, primarily caused by their rising global demand for weight loss, has ended. As more consumers seek effective solutions for weight management and diabetes treatment, the availability of these medications is likely to have a significant impact on public health.
With the introduction of discounted prices at major retailers, customers without insurance now have a viable option to access Ozempic and Wegovy. This move not only addresses the affordability issue but also aligns with a growing trend of retailers taking proactive steps to enhance healthcare access for their members.
As interest in these medications continues to grow, the landscape of weight-loss treatments may change, providing more individuals with the opportunity to manage their health effectively.